NCAPGP2

Across TCGA pan-cancer cohorts, NCAPGP2 RNA differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of NCAPGP2’s most consistent transcriptional readouts.

The strongest signal is observed in lung adenocarcinoma (LUAD), where NCAPGP2 RNA is repressed in tumor relative to normal tissue. In most cancer types NCAPGP2 is over-expressed in tumor, although a few such as LUAD and COAD show the opposite, repressed pattern.

LUAD, COAD, and LUSC are the cancer types where NCAPGP2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in NCAPGP2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LUAD	Female	III,IV	−2.223	<.001	11	view →
COAD	All	III,IV	−0.272	<.001	11	view →
LUSC	Female	II,III,IV	−1.948	<.001	9	view →
THCA	All	IV	−0.707	<.001	8	view →
KICH	Male	II,III,IV	−0.243	<.001	8	view →
PAAD	Male	All	−0.245	.010	2	view →
KIRP	Female	All	−0.165	.028	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

NCAPGP2–LUAD

Open the LUAD breakdown →